On Nov. 6, Moderna raised its forecast for 2026 revenue growth to 15%–25% after reporting $1.3 billion in third-quarter revenue and a $162 million profit.
The results were helped by stronger vaccine sales and lower costs. Revenue rose 29% from a year earlier. The increase came mainly from higher COVID vaccine sales in international markets and deliveries through government partnerships.
U.S. revenue was $780 million. International markets generated $533 million. The company earned 38 cents per share, compared with a loss of 51 cents per share in the same quarter last year.
The results beat analysts’ revenue estimate of $885.1 million. They also beat analysts’ expectation of a $1.25-per-share loss. CEO Stéphane Bancel credited newer products and a wider international reach.
He also noted that Moderna is seeing sales of its updated COVID vaccine for more of the year. Moderna also improved its 2026 forecast for operating costs by about $200 million. The company raised its expected year-end cash balance to $8.1 billion–$8.3 billion.
Moderna expects its new flu shot to have a limited launch in the United States this season. Its approval came after vaccine contracts had already been set.